# Adinvest AG

> Adinvest AG is a VC fund in Zug backing Oncology, Software and Life Science. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Zug, Switzerland
- Total investments: 2
- Last investment: Dec 2021
- Lead investor: 50%
- Last updated: Aug 2026
- Website: http://adinvest.ch/

Adinvest AG is a VC fund in Zug focused on Oncology and Software. Adinvest AG focuses on venture capital investments in early-stage companies and provides asset management and corporate finance services. The firm was founded by Neil Sunderland. Adinvest also offers advisory services covering mergers & acquisitions, financial engineering, private placements, IPOs, due diligence, tax consulting, and managementconsulting.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Oncology | 1 | 50% |
| Software | 1 | 50% |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Promontory Therapeutics | Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages indealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors. | $37M | Series A | Dec 14, 2021 |  |
| Invenda Group | Invenda Group is disrupting the vending machine industry with connected smart technology by building a cohesive software solution that offers interoperability with industry-leading solutions. | $2.3M | Seed | May 14, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [Mutschler Ventures AG](https://shizune.co/investors/profile/mutschler-ventures-ag) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Adinvest AG invest in?

Adinvest AG invests primarily in Oncology, Software and Life Science startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Adinvest AG last invest?

The most recent investment recorded for Adinvest AG closed in Dec 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co